Cytokinetics, Incorporated
Cytokinetics initiates study for symptomatic obstructive cardiomyopathy.
1 source·30/09, 11:42·finviz.com
FDA approves MYQORZO for obstructive hypertrophic cardiomyopathy.
1 source·19/12, 21:02·sec.gov
Positive opinion for MYQORZO® marketing authorization.
Cytokinetics appoints new Chief Legal and Administrative Officer.
1 source·14/11, 21:10·sec.gov
10-Q form submitted!
1 source·05/11, 21:32·sec.gov
Cytokinetics announces third quarter financial results.
1 source·05/11, 21:10·sec.gov
Cytokinetics issued $750 million in convertible senior notes.
1 source·22/09, 10:04·sec.gov
FDA meeting suggests positive trajectory for aficamten approval.
1 source·16/09, 20:10·sec.gov
Positive data on aficamten presented at ESC Congress.
1 source·08/09, 21:04·sec.gov
Aficamten data presented at cardiology congress.
1 source·03/09, 10:02·sec.gov
·sec.gov·19/12, 00:00
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
·finviz.com·10/06, 11:38